Parsabiv

Parsabiv Overdosage

etelcalcetide

Manufacturer:

Amgen

Distributor:

Zuellig
/
Agencia Lei Va Hong
Full Prescribing Info
Overdosage
Overdose of etelcalcetide may lead to hypocalcaemia with or without clinical symptoms and may require treatment. In the event of overdose, serum calcium should be checked and patients should be monitored for symptoms of hypocalcaemia (see Precautions) and appropriate measures should be taken (see Dosage & Administration). Although Parsabiv is cleared by dialysis, haemodialysis has not been studied as a treatment for overdose. Single doses up to 60 mg and multiple doses up to 22.5 mg 3 times a week at the end of dialysis in patients receiving haemodialysis were safely administered in clinical trials.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in